Clinical Trial Update: Efficacy, Tolerability, and Pharmacokinetics of Multiple Doses of Oral TAK-831 in Adults With Friedreich Ataxia [Phase 2]

View source ↗

Summary

Phase 2 trial updates on multiple-dose oral TAK-831 in adults with Friedreich Ataxia, reporting efficacy, tolerability, and pharmacokinetics.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Friedreich Ataxia

Drugs mentioned

• TAK-831 (TAK-831)

Snippet

Sponsor: Neurocrine Biosciences | Conditions: Friedreich Ataxia | Phase 2 | Status: COMPLETED | Results posted: 2019-12-19